Update shared on24 Sep 2025
Fair value Decreased 0.27%Both the Discount Rate and Net Profit Margin for Swedish Orphan Biovitrum remained essentially stable, supporting the analyst consensus price target, which saw only a marginal decrease from SEK341.18 to SEK340.27.
What's in the News
- Tryngolza (olezarsen) approved in the EU as adjunct therapy for adults with genetically confirmed familial chylomicronemia syndrome (FCS), based on positive Phase 3 data; Sobi holds exclusive commercialization rights outside the U.S., Canada, and China.
- U.S. FDA accepted Biologics License Application for NASP (formerly SEL-212) for uncontrolled gout, with a target action date of June 2026; Phase 3 trials met primary endpoints for serum uric acid reduction.
- Doptelet (avatrombopag) approved by the FDA for pediatric thrombocytopenia in patients one year and older with chronic immune thrombocytopenia; Doptelet Sprinkle oral granules formulation approved for ages one to less than six.
- Sobi maintained unchanged 2025 earnings guidance, expecting high single-digit percentage revenue growth at constant exchange rates.
- Gamifant (emapalumab-lzsg) approved by the FDA for adult and pediatric patients with HLH/MAS in Still’s disease, with positive efficacy and safety results from pivotal studies.
Valuation Changes
Summary of Valuation Changes for Swedish Orphan Biovitrum
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from SEK341.18 to SEK340.27.
- The Discount Rate for Swedish Orphan Biovitrum remained effectively unchanged, moving only marginally from 4.98% to 5.06%.
- The Net Profit Margin for Swedish Orphan Biovitrum remained effectively unchanged, moving only marginally from 20.80% to 20.49%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.